DBV Share Price Performance
€2.50
0.85 (51.21%)
34.3% undervalued intrinsic discount
€3.80
Fair Value
Price €2.50
AnalystConsensusTarget €3.80
AnalystLowTarget €1.00
AnalystHighTarget €5.50
Fair Value€3.80
Share Pricen/a
New Narrative • Aug 14
DBV Technologies S.A. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
DBV Community Narratives
AN
Fair Value
·Fair Value €3.8 34.3% undervalued intrinsic discount
Pediatric Peanut Allergy Treatment Pipeline Will Support A Long-Term Bullish Thesis
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value €1 149.8% overvalued intrinsic discount
Reliance On Single Allergy Patch Will Likely Limit Future Earnings Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value €5.5 54.6% undervalued intrinsic discount
Epicutaneous Allergy Therapy Will Target Stable Pediatric Market And Transform Long Term Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Reliance On Single Allergy Patch Will Likely Limit Future Earnings Potential
DBV Technologies is betting heavily on a single skin patch to treat peanut allergies in young children, and any setback with regulators could leave it without a solid backup plan. At the same time, rivals and slower-than-hoped adoption could make it harder to turn a future approval into lasting profits.Read more
AN
€1
149.8% overvalued intrinsic discount
Fair Value
Profit Margin
6.59%
Future PE
44.35x
Price in 2029
€0.68
Pediatric Peanut Allergy Treatment Pipeline Will Support A Long-Term Bullish Thesis
A peanut allergy skin patch for kids could turn DBV Technologies from a research-focused biotech into a real product company, with a large, steady group of families who may need treatment for years. The upside hinges on getting the patch approved and quickly adopted by doctors and insurers before competing treatments take share.Read more
AN
€3.8
34.3% undervalued intrinsic discount
Fair Value
Profit Margin
24.85%
Future PE
16.99x
Price in 2029
€2.56
Epicutaneous Allergy Therapy Will Target Stable Pediatric Market And Transform Long Term Prospects
DBV Technologies is betting that a skin patch for peanut allergy can become a go-to option for children, and it’s gearing up to move from years of testing into a real product launch. The big upside hinges on smooth regulator sign-off and convincing long-term results across younger age groups, while delays, safety questions, and tough competition could hold the business back.Read more
AN
€5.5
54.6% undervalued intrinsic discount
Fair Value
Profit Margin
48.46%
Future PE
9.12x
Price in 2029
€3.71
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Reliance On Single Allergy Patch Will Likely Limit Future Earnings Potential
Fair Value: €1 149.8% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Pediatric Peanut Allergy Treatment Pipeline Will Support A Long-Term Bullish Thesis
Fair Value: €3.8 34.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Epicutaneous Allergy Therapy Will Target Stable Pediatric Market And Transform Long Term Prospects
Fair Value: €5.5 54.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
DBV Technologies S.A. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Oct 28, 2026
- -0.59
- 100.00%
- -3,493.78%
- 0%
About DBV
- Founded
- 2002
- Employees
- 170
- CEO
- WebsiteView website
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Recent DBV News & Updates
New Narrative • Jul 31
